세계의 항균제 내성 진단 시장 : 제품 유형별, 검사 장소별, 시설 유형별 - 예측(2025-2030년)

The Antimicrobial Resistance Diagnostic Market was valued at USD 4.53 billion in 2023, expected to reach USD 4.75 billion in 2024, and is projected to grow at a CAGR of 6.14%, to USD 6.88 billion by 2030.

The antimicrobials resistance (AMR) diagnostics market encompasses technologies and products aimed at identifying resistance patterns in pathogens to inform treatment decisions. This includes molecular tests, immunoassays, and rapid diagnostic kits. The necessity for these diagnostics is underscored by the rising prevalence of drug-resistant infections, which pose substantial public health challenges. AMR diagnostics are critical in both clinical settings-where they guide appropriate antibiotic usage-and in public health surveillance, helping track resistance patterns worldwide. The market serves various end-users, including hospitals, clinics, laboratories, academic institutions, and research organizations. Significant growth factors include increasing awareness of AMR issues, governmental initiatives, advancements in diagnostic technologies, and the necessity to reduce misuse and overuse of antibiotics. The rapid development of point-of-care diagnostics and integration of AI in diagnostic processes present promising opportunities for stakeholders. However, challenges persist, including high costs of advanced diagnostic equipment, regulatory hurdles, and the need for investment in infrastructure, particularly in low-income regions. Key growth opportunities exist in developing cost-effective, easy-to-use point-of-care devices suitable for resource-limited settings. Moreover, there is potential in the development of next-generation sequencing technologies that can provide comprehensive resistance profiles swiftly. Businesses should prioritize innovation in rapid, cost-effective diagnostics, which align with global healthcare needs. Increasing collaboration between public and private sectors can enhance research and development efforts, thus expanding market reach. While the market offers robust potential, its growth can be stymied by logistical barriers and the slow adoption rate in some regions due to economic constraints. Therefore, focusing on educating healthcare providers about the benefits of AMR diagnostics and creating awareness programs to enhance adoption could be strategic. Overall, forging partnerships, investing in cutting-edge technology, and addressing region-specific challenges are pivotal for market advancement.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antimicrobial Resistance Diagnostic Market

The Antimicrobial Resistance Diagnostic Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of antimicrobial resistance leading to a higher demand for diagnostic solutions
  • Government initiatives and funding to combat antimicrobial resistance through improved diagnostics
  • Growing awareness among healthcare professionals and public about the importance of early and accurate antimicrobial resistance diagnosis
• Market Restraints
  • High cost associated with advanced diagnostic tests
• Market Opportunities
  • Cross-sector partnerships to combat antimicrobial resistance using comprehensive diagnostic approaches
  • Investment opportunities in startups focused on antimicrobial resistance diagnostic innovations
• Market Challenges
  • Lack of standardization protocol and regulatory harmonization across various region

Porter's Five Forces: A Strategic Tool for Navigating the Antimicrobial Resistance Diagnostic Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antimicrobial Resistance Diagnostic Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antimicrobial Resistance Diagnostic Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antimicrobial Resistance Diagnostic Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antimicrobial Resistance Diagnostic Market

A detailed market share analysis in the Antimicrobial Resistance Diagnostic Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antimicrobial Resistance Diagnostic Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antimicrobial Resistance Diagnostic Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antimicrobial Resistance Diagnostic Market

A strategic analysis of the Antimicrobial Resistance Diagnostic Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antimicrobial Resistance Diagnostic Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Accelerate Diagnostics, Beckman Coulter, Becton, Dickinson and Company, BioFire Diagnostics, bioMerieux, Bruker Corporation, Cardinal Health, Cepheid, GenMark Diagnostics, GSK plc, Hoffmann-La Roche, Hologic, Inc., Luminex Corporation, Merck & Co., Inc., OpGen, Qiagen, Siemens Healthineers, T2 Biosystems, and Thermo Fisher Scientific.

Market Segmentation & Coverage

This research report categorizes the Antimicrobial Resistance Diagnostic Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product Type, market is studied across Assays & Reagents and Diagnostic Tools. The Assays & Reagents is further studied across Biosensors and Monoclonal Anitbodies. The Diagnostic Tools is further studied across Instruments and Software & Services.
• Based on Testing Location, market is studied across Laboratory Testing and Point-Of-Care Testing. The Laboratory Testing is further studied across Isothermal Nucleic Acid Amplification Technology (INAAT) and Polymerase Chain Reaction (PCR). The Point-Of-Care Testing is further studied across Immunoassays and Microarray.
• Based on Facility Type, market is studied across End User and Research. The End User is further studied across Diagnostic Laboratories and Hospitals And Clinics. The Research is further studied across CROs and Research Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of antimicrobial resistance leading to a higher demand for diagnostic solutions
    • 5.1.1.2. Government initiatives and funding to combat antimicrobial resistance through improved diagnostics
    • 5.1.1.3. Growing awareness among healthcare professionals and public about the importance of early and accurate antimicrobial resistance diagnosis
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with advanced diagnostic tests

• 5.1.3. Opportunities
  • 5.1.3.1. Cross-sector partnerships to combat antimicrobial resistance using comprehensive diagnostic approaches
  • 5.1.3.2. Investment opportunities in startups focused on antimicrobial resistance diagnostic innovations
• 5.1.4. Challenges
  • 5.1.4.1. Lack of standardization protocol and regulatory harmonization across various region
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Antimicrobial Resistance Diagnostic Market, by Product Type

• 6.1. Introduction
• 6.2. Assays & Reagents
  • 6.2.1. Biosensors
  • 6.2.2. Monoclonal Anitbodies
• 6.3. Diagnostic Tools
  • 6.3.1. Instruments
  • 6.3.2. Software & Services

7. Antimicrobial Resistance Diagnostic Market, by Testing Location

• 7.1. Introduction
• 7.2. Laboratory Testing
  • 7.2.1. Isothermal Nucleic Acid Amplification Technology (INAAT)
  • 7.2.2. Polymerase Chain Reaction (PCR)
• 7.3. Point-Of-Care Testing
  • 7.3.1. Immunoassays
  • 7.3.2. Microarray

8. Antimicrobial Resistance Diagnostic Market, by Facility Type

• 8.1. Introduction
• 8.2. End User
  • 8.2.1. Diagnostic Laboratories
  • 8.2.2. Hospitals And Clinics
• 8.3. Research
  • 8.3.1. CROs
  • 8.3.2. Research Institutes

9. Americas Antimicrobial Resistance Diagnostic Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Antimicrobial Resistance Diagnostic Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Antimicrobial Resistance Diagnostic Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Accelerate Diagnostics
• 3. Beckman Coulter
• 4. Becton, Dickinson and Company
• 5. BioFire Diagnostics
• 6. bioMerieux
• 7. Bruker Corporation
• 8. Cardinal Health
• 9. Cepheid
• 10. GenMark Diagnostics
• 11. GSK plc
• 12. Hoffmann-La Roche
• 13. Hologic, Inc.
• 14. Luminex Corporation
• 15. Merck & Co., Inc.
• 16. OpGen
• 17. Qiagen
• 18. Siemens Healthineers
• 19. T2 Biosystems
• 20. Thermo Fisher Scientific